AI Agents in Pharmacovigilance: Use Cases and Guide

TL;DR

• AI agents can support pharmacovigilance from adverse-event intake through signal review and reporting.
• Suitable first use cases are repetitive, high-volume tasks with clear review and escalation rules.
• Agents can prioritize potential safety signals, but they cannot independently confirm causality.
• Human review remains essential for case validity, medical assessment, signal validation, and regulatory decisions.
• Organizations should begin with a controlled pilot, validate performance, and expand only when quality and compliance targets are met.

---

Introduction

AI agents in pharmacovigilance are systems that interpret safety data, coordinate multi-step workflows, and support tasks such as ICSR intake, literature screening, MedDRA coding, signal review, and regulatory reporting. They can reduce repetitive work, but they should support rather than replace qualified pharmacovigilance professionals. Reliable use requires validated performance, human medical review, traceable decisions, controlled access, and continuous monitoring.

---

What Are AI Agents in Pharmacovigilance?

According to the World Health Organization’s pharmacovigilance overview, pharmacovigilance covers the detection, assessment, understanding, and prevention of adverse effects or other medicine-related problems.

AI agents extend conventional automation by interpreting unstructured information, using approved tools, and coordinating multiple steps within a defined pharmacovigilance workflow.

For example, an agent may:

1. Monitor an approved safety mailbox.
2. Identify a potential adverse-event report.
3. Extract patient, reporter, product, event, and date information.
4. Check whether required information is missing.
5. Search for potential duplicate cases.
6. Suggest standardized medical coding.
7. Route the case to a qualified reviewer.
8. Record the actions in an audit trail.

The agent should not be treated as an autonomous medical decision-maker. The organization and its designated pharmacovigilance professionals remain responsible for case quality, regulatory compliance, benefit-risk decisions, and patient safety.

This article focuses specifically on pharmacovigilance workflows. For the broader classification of agent systems, read the guide to types of AI agents.

---

Why Do Pharmacovigilance Teams Need AI Agents?

Pharmacovigilance teams process safety information from spontaneous reports, medical literature, clinical programs, call centers, patient-support channels, and healthcare data.

Much of this information arrives as unstructured emails, PDFs, forms, medical narratives, or transcripts. This creates pressure around:

• Repetitive data entry and quality checks
• Time-sensitive ICSR triage
• Duplicate-case detection
• Literature screening
• Consistent medical coding
• Signal prioritization
• Regulatory submission timelines
• Audit-ready documentation

The FDA Emerging Drug Safety Technology Program identifies potential AI applications in adverse-event intake, data entry, ICSR processing, evaluation, submission, and signal detection. The FDA also emphasizes human-led governance, data quality, transparency, model evaluation, and continuous monitoring.

---

Which Pharmacovigilance Tasks Can AI Agents Support?

Pharmacovigilance workflow	Agent-supported activity	Required human control
Case intake	Extract information from emails, forms, PDFs, and transcripts	Confirm case validity and missing information
Case triage	Suggest seriousness, urgency, and routing	Approve final classification
Duplicate detection	Compare new reports with existing cases	Review probable matches
Medical coding	Suggest suitable MedDRA terms	Qualified coding review
Literature screening	Search, classify, summarize, and route publications	Confirm relevance and reportability
Narrative drafting	Prepare narratives from verified case fields	Medical and quality review
Signal detection	Identify and prioritize unusual patterns	Clinical validation and benefit-risk assessment
Regulatory reporting	Validate fields and monitor deadlines	Final compliance approval

How do agents support case intake and coding?

An AI agent can convert unstructured source documents into structured ICSR fields, identify missing information, suggest MedDRA terms, and prepare a draft case narrative.

A safer initial deployment is draft mode. The agent prepares the case, but a trained pharmacovigilance reviewer approves it before information is committed to the safety database or submitted to a regulator.

How can agents improve literature screening?

Agents can monitor approved literature sources, remove duplicate results, classify publications by relevance, extract potential safety information, and prepare summaries.

Human reviewers must still determine whether an article contains a valid report, requires follow-up, affects listedness, or changes the known safety profile.

Can AI agents detect safety signals?

AI agents can compare internal cases, regulatory data, medical literature, and other approved sources to identify patterns requiring further investigation.

They may prioritize potential signals or prepare supporting evidence. However, a statistical association does not prove that a medicine caused an adverse event. Qualified experts must validate the finding, assess alternative explanations, and decide whether regulatory or risk-management action is required.

---

How Do AI Agents Integrate With Existing PV Systems?

AI agents should operate as controlled components around existing safety databases, literature-monitoring systems, coding dictionaries, quality-management systems, and regulatory submission platforms.

A reliable workflow should:

1. Use only approved data sources.
2. Preserve the original source document.
3. Record which model and version processed the case.
4. Store extracted fields, confidence levels, and supporting evidence.
5. Require human review at defined decision points.
6. Log every edit, approval, rejection, and submission.
7. Support rollback and incident investigation.

Outputs must map correctly to the organization’s safety-database fields and reporting formats.

The CIOMS Working Group XIV report on AI in pharmacovigilance recommends clearly defining the context in which an AI system may be used, along with its limitations, precautions, and operating conditions.

---

What Are the Benefits and Risks?

Potential benefit	Risk that must be controlled
Faster repetitive processing	Incorrect extraction or classification
More consistent workflows	Bias from incomplete or unrepresentative data
Wider literature and safety-data coverage	False-positive or missed signals
Better deadline tracking	Integration and validation complexity
Scalable handling of case-volume increases	Model drift and changing performance
More traceable digital workflows	Privacy, cybersecurity, and access risk

AI agents may increase processing capacity, but they do not remove an organization’s pharmacovigilance obligations.

Organizations should also avoid claiming that AI automatically improves accuracy. Any improvement should be demonstrated through validation against representative cases, languages, products, and safety scenarios.

---

How Can Organizations Implement AI Agents Safely?

Step 1: Choose a narrow use case

Begin with a frequent task that has a stable procedure and measurable outcome.

Suitable starting points may include:

• Intake-field extraction
• Literature prioritization
• Duplicate suggestions
• Missing-field identification
• Draft narrative preparation

Avoid beginning with autonomous causality assessment, final signal validation, or unsupervised regulatory submission.

Step 2: Define the context of use

Document:

• Intended users
• Permitted data sources
• Allowed actions
• Excluded cases
• Human-review points
• Escalation conditions
• Required evidence
• Expected output
• Failure-handling procedures

Step 3: Validate representative cases

Test the system using:

• Common case narratives
• Difficult or ambiguous narratives
• Missing information
• Duplicate and follow-up reports
• Special situations
• Non-English content
• Serious and unexpected events
• Integration failures

Measure extraction accuracy, coding agreement, triage performance, false negatives, false positives, and failure behavior.

Step 4: Keep human review and traceability

Qualified review should remain mandatory for medical and regulatory decisions, including:

• Case validity
• Seriousness
• Expectedness
• Listedness
• Causality
• Medical coding
• Signal validation
• Final regulatory submission

Use role-based access, encryption, source evidence, audit logs, version control, change management, incident response, and continuous monitoring.

---

Practical Implementation Lesson

In regulated AI systems, the model is only one part of reliability. Identity controls, source traceability, privacy protection, prompt-injection defense, and audit logging are equally important.

Creole Studios applied these principles while developing a secure AI RAG system. The system combined role-based retrieval, PII masking, prompt-injection protection, and audit logging. Testing covered six malicious-query categories and seven types of sensitive information.

Although this was not a pharmacovigilance application, the security-by-design pattern is relevant when AI systems process sensitive patient or safety information.

---

What Should Pharmacovigilance Teams Measure?

Track quality, operational, safety, and governance metrics together:

• Processing time per case
• Field-level extraction accuracy
• Medical-coding agreement
• Duplicate precision and recall
• False-negative rate for serious or reportable cases
• Human override rate
• Escalation rate
• Submission timeliness
• Audit-trail completeness
• Model and integration failures
• Cost per reviewed case

Time saved alone is not a sufficient success metric. A faster system that misses critical information or produces unreviewable outputs is not an improvement.

Use the AI agent development cost guide to plan for development, integration, validation, infrastructure, security, monitoring, and ongoing maintenance.

---

What Is the Future of AI in Pharmacovigilance?

The direction is toward more coordinated case workflows, wider use of real-world data, continuous safety monitoring, and stronger decision support.

The FDA now has a program dedicated to emerging drug-safety technology, and CIOMS published a dedicated report on AI in pharmacovigilance in 2025. These developments indicate growing regulatory attention, but they do not remove the need for validation, accountability, and human oversight.

Near-term adoption should remain human-led. Organizations that define narrow contexts of use, validate performance, and maintain complete auditability will be better positioned than those pursuing unrestricted autonomy.

Explore real-world AI agent case studies to understand how controlled agents support other technical and business workflows.

---

Frequently Asked Questions

Can AI agents replace pharmacovigilance professionals?

No. AI agents can automate repetitive work and prepare recommendations, but qualified professionals remain responsible for medical review, signal validation, benefit-risk decisions, compliance, and patient safety.

Can AI agents detect adverse-event signals?

They can identify and prioritize patterns that require investigation. They cannot independently establish causality or confirm a safety signal without expert clinical review.

Can AI agents integrate with existing safety databases?

Yes, when the system supports the required APIs, field mappings, access controls, validation, audit trails, and structured reporting requirements.

What is a suitable first pharmacovigilance use case?

Start with a frequent, well-documented, measurable task with manageable risk. Intake extraction, literature prioritization, missing-field checks, and duplicate suggestions are generally better starting points than autonomous medical assessment.

What data can pharmacovigilance agents process?

Depending on the approved context of use, agents may process ICSRs, literature, medical narratives, forms, emails, call transcripts, structured safety records, product information, and regulatory data.

---